ABSTRACT
Introduction Chronic pain is an extremely prevalent public health issue. However, the underlying mechanisms are poorly understood, thus limiting effective treatment options. Both preclinical studies, and more recent clinical imaging studies, suggest that glia-mediated neuroinflammation may be implicated in chronic pain, and therefore might be a potential treatment target. However, it is currently unknown whether modulating neuroinflammation effectively alleviates pain in humans. This trial tests the hypothesis that minocycline, an FDA-approved tetracycline antibiotic and effective glial cell inhibitor in animals, reduces neuroinflammation and may reduce pain symptoms in humans with chronic low back pain.
Methods and analysis This study is a randomized, double-blind, placebo-controlled clinical trial. Subjects, aged 18-65, with a confirmed diagnosis of chronic (≥ six months) low back pain (cLBP) and a self-reported pain rating of at least four out of ten (for at least half of the days during an average week) are enrolled via written, informed consent. Eligible subjects are randomized to receive a 14-day course of either active drug (minocycline) or placebo. Before and after treatment, subjects are scanned with integrated Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI) using [11C]PBR28, a second-generation radiotracer for the 18 kDa translocator protein (TSPO), which is highly expressed in glial cells and thus a putative marker of neuroinflammation. Pain levels are evaluated via daily surveys, collected seven days prior to the start of medication, and throughout the 14 days of treatment. General linear models are used to assess pain levels and determine the treatment effect on brain (and spinal cord) TSPO signal.
Ethics and dissemination This study was approved by the Massachusetts General Hospital Institutional Review Board (Protocol Number: 2017P000179) and the U.S. Food and Drug Administration (IND Number: 142546). The results of the study will be disseminated via publications in peer-reviewed journals, presentations at conferences globally, and through various media.
Trial registration number ClinicalTrials.gov (NCT03106740)
Strengths and limitations of this study
This is the first project to image the potential neuro-inflammatory effect of minocycline in a chronic pain condition.
The use of simultaneous PET/MRI allows us to collect additional, ancillary MRI data that can be used to perform a comprehensive neurophysiological assessment of subjects.
The sample size (n∼50 per group) is relatively small to detect a clinical response. An additional limitation is the relatively short treatment duration (i.e., 2-weeks).
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
IND142546, NCT03106740
Funding Statement
This work was supported by 1R01NS095937-01A1, awarded by the National Institute of Health (NIH). This grant supported all subject study-related drugs, devices, procedures, tests, and visits.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Massachusetts General Brigham Institutional Review Board (Protocol: 2017P000179)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data and materials used in the analyses may be provided by Marco L. Loggia and Massachusetts General Hospital, pending scientific review and a completed data use agreement/material transfer agreement beginning one year after publication of the results. Requests for all materials should be submitted to Marco L. Loggia at marco.loggia{at}mgh.harvard.edu.